Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TempraMed Technologies Ltd. ( (TSE:VIVI) ) has issued an update.
TempraMed Technologies has received independent validation from the U.S.-based Validation Institute confirming that its payor return-on-investment model for VIVI Cap and VIVI Epi meets or exceeds industry standards for healthcare economic analysis. The validated model indicates that payors covering these devices for patients using temperature-sensitive injectable medications can achieve significant net cost savings through reduced drug waste, fewer adverse events, better adherence and lower anxiety-related healthcare utilization. Backed by this validation, TempraMed is advancing discussions with U.S. healthcare payors to launch pilot programs that will test real-world savings and are expected to accelerate reimbursement decisions, potentially unlocking scalable, reimbursement-driven growth and positioning the company’s products as standard-of-care solutions across multiple chronic disease categories.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a medical-technology company focused on innovative, temperature-controlled medication storage solutions for temperature-sensitive injectable drugs such as insulin, GLP-1 therapies, biologics and epinephrine. The company develops patented, FDA-registered, battery-free thermal insulation devices, including its flagship VIVI Cap and VIVI Epi products, targeting patients, payors and pharmaceutical partners that seek to improve drug effectiveness, adherence and overall treatment value.
Average Trading Volume: 40,873
For an in-depth examination of VIVI stock, go to TipRanks’ Overview page.